Gene-directed enzyme prodrug therapy (GDEPT) based on the Escherichia coli enzyme, purine nucleoside phosphorylase (PNP), provides a novel strategy for treating slowly growing tumors like prostate cancer (CaP). PNP converts systemically administered prodrug, fludarabine phosphate, to a toxic metabolite, 2-fluoroadenine, that kills PNP-expressing and nearby cells by inhibiting DNA, RNA and protein synthesis. Reporter gene expression directed by a hybrid prostatedirected promoter and enhancer, PSMEPb, was assayed after plasmid transfection or viral transduction of prostate and nonCaP cell lines. Androgen-sensitive (AS) LNCaP-LN3 and androgen-independent (AI) PC3 human CaP xenografts in nude mice were injected intratumorally with an ovine atadenovirus vector, OAdV623, that carries the PNP gene under PSMEPb, formulated with cationic lipid for enhanced infectivity. Fludarabine phosphate was then given intraperitoneally for 5 days at 75 mg/m 2 /day. PNP expression was evaluated by enzymic conversion of its substrate using reverse phase HPLC. OAdV623 showed excellent in vitro transcriptional specificity for CaP cells. In vivo, expression of PNP persisted for 46 days after OAdV623 injection and a single treatment provided 100% increase in tumor doubling time and 450% inhibition of tumor growth for both LNCaP-LN3 and PC3 lines, with increased tumor necrosis and apoptosis and decreased tumor cell proliferation. OAdV623 significantly suppressed the growth of AS and AI human CaP xenografts in mice.
Introduction
Prostate cancer (CaP) is the second highest cause of cancer mortality in men in Western society. 1 Organconfined CaP is treatable, but once the cancer has spread, hormonal ablation therapy is limited by the development of androgen-independent (AI) CaP. 2 New strategies are needed to improve long-term survival of patients with advanced disease and to complement other therapies. Emerging gene therapies including gene-directed enzyme prodrug therapy (GDEPT) should be suitable for CaP, as the prostate is a nonessential organ.
GDEPT systems delivered via human adenovirus vectors have been described. [3] [4] [5] [6] In this work, we utilize a gene under the control of a hybrid prostate-specific enhancer/promoter 7 and delivered by a recombinant ovine atadenovirus (OAdV). This virus is the prototype of a new genus that is distinct from the mastadenoviruses that contains all human adenoviruses. OAdV vectors escape pre-existing antibodies in sera that neutralize human adenoviruses 8 and have a favorable biosafety profile: they are replication abortive in human cells, 9 lack transforming activity 10 and are not complemented in coinfected cells by replicating human adenoviruses. 11, 12 OAdV can also infect cells in human prostate biopsies maintained in organ culture. 13 Our GDEPT strategy uses the Escherichia coli purine nucleoside phosphorylase (PNP) gene, exploiting its different substrate specificity versus the human PNP homologue. Fludarabine (transformed by dephosphorylation of fludarabine phosphate in vivo), which is approved clinically for leukemia treatment, is used as the prodrug substrate. Once translated, PNP converts fludarabine to a toxic metabolite, 2-fluoroadenine (2FA) that, as a base analog, inhibits reactions involving ATP. Thus, cycling and nonproliferating cells are killed, primarily by inhibition of protein and RNA synthesis.
14 2-FA is also a more potent (B100-fold) cell growth inhibitor than 6-methylpurine (6MP). 4, 14 The advantages of PNP-GDEPT are first, that the treatment can kill cells independently of proliferation; 14 for CaP, as few as 2% of cells may be in s phase. 15 Second, not all tumor cells need be transduced to produce a therapeutic benefit as 2-FA is nonphosphorylated and readily diffuses across cell membranes, providing an excellent bystander effect. In vitro, only 1% of cells need to express E. coli PNP for total cell death to occur, 16 an advantage over the thymidine kinase (HSVtk)/ganciclovir suicide system, where the toxic product requires cell-to-cell contact or gap junctions to spread to nearby cells. Our previous studies with PNP-GDEPT demonstrated marked suppression of an aggressive murine CaP in immunocompetent mice. 17 We isolated an enhancer (PSME) from the third intron of the prostate-specific membrane antigen (PSMA) gene, FOLH1 (folate hydrolase gene).
7 PSME promoted high level expression in CaP cell lines, but was essentially inactive or repressed expression in nonprostate cell lines. PSME also activated transcription from several heterologous promoters including that of the rat probasin (Pb) gene. The combination of PSME with Pb produced very high levels of prostate cell-specific expression both in the presence and absence of androgen. Therefore, we have used these elements in OAdV623 to examine the effects of PNP-GDEPT on the growth of androgen-sensitive (AS) LNCaP-LN3 cells (abbreviated LN3) and AI PC3 human CaP cell lines grown as xenografts in nude mice. OAdV623 was formulated in a buffer containing cationic lipid that improves OAdV infectivity in certain cell types (Cameron et al, in preparation), enhancing potential utility. To understand how cell killing is mediated by PNP-GDEPT, we have determined its effects on the extent of necrosis, apoptosis and tumor cell proliferation.
Results
Tissue specificity of the PSME/Pb promoter in vitro
To examine promoter specificity, we used PSMEPb-or RSV-luciferase expression cassettes. A 1 kb, instead of 1.6 kb PSME region, 7 was used to reduce cassette size for inclusion in OAdV. Plasmids were transfected into different cells, luciferase activities were assayed and the amount of PSMEPb-luc was expressed as a percentage of RSV-luc in the same cell line (Table 1 , right-hand column). The PSMEPb elements showed a high level of expression in LNCAP prostate cells (77% of RSV expression) with very low expression levels (0.06-1.0%) observed in nonprostate cells. Low, but significant expression (5.7%) occurred in PC3 cells that do not express the PSMA gene.
Similarly, the PNP gene was linked to PSMEPb or RSV promoters and cloned into the OAdV genome producing OAdV623 and OAdV220, respectively (Figure 1 ). To assess expression specificity in the viral context, prostate and nonprostate cell lines were infected with OAdV220 or OAdV623 and PNP activity was assayed. To correct for different infection efficiencies between cell types, expression levels were normalized to those obtained after infection with OAdV220. This analysis is therefore independent of the different gene insertion sites used in the two viruses ( Figure 1 ). Expression of OAdV623 was highest, 3.6 (average)-5.5-fold that of the RSV promoter, in the two CaP cell lines that express PSMA (Table 1) , and lower in the AI cell line, PC3, which does not. Nevertheless, some expression was seen in the PC3 cells. In most nonprostate cell lines, activity was o10% of that seen in PSMA-expressing prostate cells. Thus, substantial prostate-specific expression was obtained in vitro with OAdV623.
PNP expression in vivo
To confirm gene transfer by different vector doses and to examine the kinetics of gene expression in vivo, PNP (Figure 2b ). This confirmed that OAdV623 effectively delivered the PNP gene in vivo and that PNP activity persisted for at least 6 days. However, the high level of activity in PC3 cells was somewhat unexpected based on the data obtained in vitro (Table 1) .
GDEPT efficacy on AS LN3 tumor growth
Our previous data from work in immunocompetent and nude mice showed that injection of homologous virus alone did not affect tumor growth. 4, 17 Fludarabine alone also did not significantly affect LN3 tumor growth compared to vehicle control (Figure 3a) . Tumor volume in the GDEPT group was suppressed from day 15 through day 24, and in the resulting % tumor growth inhibition analysis, this reached statistical significance on day 22 (Po0.05; Table 2 ). Tumors in the GDEPT group took more than twice as long as the vehicle control to double in size, with a tumor growth delay index of 2.3 (Table 3 ). Three GDEPT-treated mice were cured of their tumors by day 17; control groups showed no cures.
GDEPT efficacy on AI PC3 tumor growth
At both 10 10 and 3.19 Â 10 10 VP, GDEPT significantly suppressed PC3 tumor growth for at least 15 days, following which tumor growth rate was similar in all groups (Figure 3b ). Analysis of tumor growth inhibition showed that tumors treated with 10 10 VP were 41-46% smaller compared to vehicle control, for at least 14 days of the treatment period (days 13-27) (Po0.001, Table 2 ). Even greater reduction in tumor size was observed in tumors administered with the higher dose, showing a clear dose-response to the treatment, although this was not statistically significant. Compared to the vehicle control, tumors in both of the GDEPT groups took more than twice as long to double in size (Table 3) . Two tumors were cured after days 18 and 54, respectively. 
Histology
Hematoxylin and eosin (H&E)-stained tumor sections from three mice per group, evaluated on days 3 and 7 after vector treatment, showed different responses in LN3 and PC3 tumors. On day 3, LN3 tumors from mice given GDEPT showed less necrosis (34718%) than those from vehicle and fludarabine controls (76718 and 73713% necrosis, respectively). In contrast, GDEPT-treated PC3 tumors showed significantly higher levels of necrosis on day 3 (55716, 5772% for the 1 or 3 Â 10 10 VP, respectively) when compared with vehicle (773%) and fludarabine (1075%) controls, but by day 7 and later, varying degrees of necrosis were seen. Minor to moderate immune cell infiltration was seen both at the periphery and in the center of both LN3 and PC3 tumors, but there was no difference between experimental groups. No signs of toxic damage from treatment were seen on histological assessment of other tissues, including liver, spleen, kidney, lung and gut. PC3 tumor cell growth occurred in one or two of the draining lymph nodes from three mice in both GDEPT and control groups.
Apoptosis after GDEPT
To investigate how GDEPT mediates cell death in vivo, the TUNEL assay was performed on PC3 tumors harvested 3 and 7 days after treatment. 18 Scattered 
Tumor cell proliferation after GDEPT
Ki-67 antigen is expressed in all cell cycle phases except G0; 19 Ki-67-positive cells were seen in non-necrotic areas of all tumors. After GDEPT with 10 10 or 3 Â 10 10 VP, Ki-67 expression was significantly reduced in PC3 tumors at 3 days compared with tumors of the vehicle control group (2373 and 1973 versus 3873, Po0.05), but not at day 7.
Discussion
We have previously reported that OAdV is suitable for delivering GDEPT to murine CaPs grown in immunocompetent mice. 17 As previously mentioned, the vectors have a favorable biosafety profile in human cells with respect to replication, transformation and complementation. [9] [10] [11] [12] In addition, the legitimacy of the overall PNP-GDEPT strategy has been well documented. 17, 20, 21 In this study where vector was delivered intratumorally, there was no histological evidence of treatment toxicity in liver, spleen, kidney, lung or gut. OAdV623 also successfully delivered PNP/fludarabine-GDEPT to both AS and AI human CaP xenografts producing retarded tumor growth, increased tumor doubling times and host survival. Cell death appeared to involve apoptosis and necrosis.
To limit potential GDEPT toxicity, gene expression should be maximal in the target CaP cells and minimal elsewhere in the body. Previous GDEPT studies for CaP have used regulatory sequences with no tissue-specific tropism, such as the RSV promoter 3, 5 or sequences that provide prostate-specific expression. The latter have included promoters and/or enhancers of prostate-specific antigen, PSA, 22, 23 osteocalcin, 24 caveolin 25 and Pb 20 genes. Our previous transfection studies had identified that the PSME plus the Pb promoter generated high level expression in prostate cells. Similar expression levels Prostate-targeted GDEPT for prostate cancer XY Wang et al were seen in the presence or absence of androgens; the PSME alone was repressed by androgens, while the Pb promoter was strongly stimulated. We therefore prepared an expression cassette in which the PNP gene was under the control of the PSMEPb elements. To reduce the cassette size for inclusion in OAdV, we used the core 1 kb enhancer rather than the 1.6kb PSME region previously reported. 7 Control transfections (Table 1) showed that activity and specificity were maintained with the shorter PSMEPb element. Analysis of PNP expression after infection by OAdV623 demonstrated strong specificity for PSMA-expressing cell lines, LNCaP and LN3, compared with nonprostate cell lines. However, in the viral context, the differential between prostate and nonprostate cells was lower (about three-fold) than seen in the transfection assays, (eg 20-30-fold versus an 80-100-fold difference, respectively, between MCF-7 and HEK293 cells, Table 1 ). Note that the ratio of PNP expression from OAdV220, which expresses the PNP gene under the Rous Sarcoma virus promoter, and OAdV623 in a particular cell line is independent of any differences in genome insertion site or cell harvest time.
Based on in vitro studies, compared with the SV40 enhancer/Pb promoter combination, we used previously 20 the hybrid PSMEPb combination is B10-fold more active in LNCaP cells, of similar activity in PC3 cells and shows greater specificity of expression. Given that PSMA expression is normally maintained or elevated in CaPs, the PSMEPb combination should be of considerable utility in targeting expression to human CaP as it should be much safer than a constitutive promoter, active in AS and AI tumors 7 and may be used together with androgen ablation.
Intratumoral injection resulted in delivery and expression of the therapeutic PNP gene by OAdV623 in vivo. Data from LN3 tumor-bearing mice indicated that an increased viral dose resulted in higher PNP activity, with 10 10 VP more effective than 10 8 VP. The presence of CS087 lipid enhanced OAdV623 infectivity and expression in these tumors (data not shown), an effect that is more pronounced in cells relatively lacking in viral receptors (Cameron et al, in preparation) . Studies in PC3 tumor-bearing mice showed that PNP expression was maintained in vivo over 6 days, indicating that systemic administration of prodrug from days 1 to 5 should have resulted in sustained production of its metabolite, 2-FA. The relatively high level of expression observed with OAdV623 infection of PC3 versus LN3 tumors was unexpected, based on the in vitro data from those cell lines (Table 1) . However, the two situations are not strictly comparable. Infection in vitro was performed in the absence of lipid and was therefore receptor dependent. Tumors were injected with lipid-formulated virus to promote receptor-independent infection of cells. 26 Thus, the expression in vivo results from the combined effect of infection in the presence of lipid, any modulation of PSME/Pb promoter activity in vivo, any differential retention of PNP within the tumors and the impact of the vector itself on each tumor type.
A single treatment of PNP/fludarabine-GDEPT substantially delayed and inhibited the growth of LN3 and PC3 tumors (Table 2 and 3) . Treatment was associated with increased survival of tumor-bearing mice (Figure 4a and b) and 'cures' were obtained in three LN3-bearing and two PC3-bearing mice. Study of the growth curves (eg Figure 3b) suggests that the response of LN3 tumors was more sustained than that of PC3. Growth of PC3 tumors was delayed for 2 weeks; they then regrew at the same rate as controls. With respect to efficacy, the nature of the tumor milieu, ability to distribute the vector widely throughout the tumor, prodrug penetration and the persistence of active PNP and/or 2-FA in the two tumor types are additional factors that have an impact.
It is possible that use of a higher dose of virus or fludarabine, or possibly, a further GDEPT-PNP treatment would provide increased efficacy. Our experiments using 3 Â 10 10 VP in PC3-bearing nude mice, compared with the usual dose of 1 Â 10 10 VP (to compensate for lower promoter activity) indicated a trend towards increased efficacy against tumor growth, but this was not statistically significant (Figure 3b, Table 3 ). Issues concerning the dose of fludarabine used in mice have previously been discussed. 17 Mice have a fludarabine tolerance around 45 times higher than man, possibly related to their contrasting distribution in the body of deaminase and phosphorylation enzymes that breakdown or metabolize fludarabine. 27, 28 The effective dose of 75 mg/m 2 / day for 5 days used in this work was only three times the dose used in humans and was much lower than that used to treat mice bearing PNP-transfected glioma cell tumors. 21 Although it can bypass pre-existing immunity to human adenoviruses, OAdV does induce an immune response when given i.v. 8 However, intratumoral injection may allow a second administration of vector, albeit with reduced efficiency. 29, 30 Little lymphocytic infiltration was seen at the tumor periphery in PC3 and LN3 tumor sections from mice given OAdV623-GDEPT, and this was similar in controls. However, there was some polymorphonuclear and monocytic infiltrate in the center of treated PC3 tumors. Our studies indicate that apoptosis was involved in killing PC3 tumor cells by OAdV623-GDEPT ( Figure 5 ). Apoptosis has been demonstrated to be important for cell killing in various gene therapy systems. 31, 32 An in vitro study of the GSVtk and PNP-GDEPT systems showed that the latter produced more tumor cell apoptosis than the former, and that the induction of apoptosis by PNP/fludarabine-GDEPT was independent of p53 status and the Fas/FasL pathway. 33 LNCaP tumors express phenotypically wild-type p53 34 and this is likely to be the case for LN3 cells. PC3 cells are p53 null. 34 OAdV623-GDEPT showed efficacy against both tumor types. However, p53 mutations, previously thought to be a late event in CaP, have been shown to predispose to cancer progression when they occur as an early event. 35 Thus, the use of the PNP/fludarabine-GDEPT could provide a substantial advantage over other GDEPT systems for patients whose CaPs express p53 mutations. Necrosis was also seen, but the effects differed in the different xenografts, possibly reflecting the natural history of the tumors. LN3 tumors became necrotic as they grew as shown by the high necrotic levels in the vehicle and fludarabine control tumors (470% necrosis). In contrast, GDEPT appeared to induce necrosis in PC3 tumors shortly after treatment, but the effects were diminished by day 7. We also observed decreased proliferation in these PC3 tumors as evidenced by staining for Ki-67 at day 3 after GDEPT, possibly Prostate-targeted GDEPT for prostate cancer XY Wang et al reflecting preferential killing of dividing cells. This effect was also absent by day 7. Studies of apoptosis and cell proliferation were not performed on LN3 tumors injected with OAdV623 in vivo. Gene therapy may be used in concert with other strategies, including intermittent hormone ablation therapy or those that enhance antitumor immunity. Our data indicate that PNP/fludarabine-GDEPT delivered by formulated OAdV623 significantly suppressed growth of both AS LNCaP-LN3 and AI PC3 human prostate cancer xenografts by a mechanism possibly involving necrosis and apoptosis. This approach has potential utility in the clinic for treating human CaPs.
Materials and methods

Cell lines and cell culture
LNCaP-LN3 (LN3) cells that are AS 36 were from Dr CA Pettaway (MD Anderson Cancer Centre, Houston, TX, USA). PC3 AI cells were from ATTC (Rockville, MD, USA). Media and chemicals were from Invitrogen, Life Technologies, Grand Island, NY, USA unless otherwise stated. LN3 cells were grown in a 1:1 mix of RPMI 1640 and F12-K and PC3 cells in RPMI 1640 medium supplemented with 2 mM L-glutamine, 0.2 M HEPES buffer solution, 50 U/ml penicillin G, 50 mg/ml streptomycin sulfate, 0.85 g/l NaHCO 3 (Sigma Chemical Co, St Louis, MO, USA) and 10% fetal bovine serum (FBS). Mycoplasma-free cells, used in log phase, were harvested with 0.05% trypsin/0.5 mM EDTA-4Na.
Nude mice
Male BALB/c athymic nude mice aged 10-17 weeks were bred at the Biological Resources Centre (BRC), University of New South Wales (UNSW), Sydney, Australia and maintained under SPF conditions on mouse chow and acidified water. Experiments were approved by the Animal Care and Ethics Committee (ACEC), University of New South Wales.
Plasmid transfections
The 1 kb PSME (nucleotides 14760-15804 of Genbank Accession number AF007544) 7 and bases 1-459 of the rat Pb promoter (Genbank Accession number S56983) (PSMEPb), identical to those used in the OAdV623, were joined to the luciferase gene in plasmid pGL3 (Promega). This plasmid and plasmids pRSVGL3 and pRSVCAT were cotransfected into different cell lines as described previously. 7 Luciferase activity directed by PSMEPb sequences or the RSV promoter was normalized with respect to the pRSVCAT expression. The ratio of these normalized expression values was calculated as (PSMEPb-luc/RSV-CAT) divided by (RSV-luc/RSV-CAT) as shown in Table 1 .
Recombinant atadenovirus production
The two viruses used in these studies both contained the PNP gene but differed in their promoters and gene the insertion site. Site III (Figure 1 ) is now preferred for reasons of general stability and expression. 37 OAdV220 uses the RSV promoter, such that PNP will be constitutively expressed, 17 whereas OAdV623 contains novel prostate-directed promoter elements described in the current paper. Gene expression cassettes were constructed in plasmids by linking the PSMEPb or RSV promoter to sequences for the E. coli DeoD gene that encodes PNP (Genbank Accession Number M60917) and the polyadenylation signal from bovine growth hormone. Recombinant OAdV623 and OAdV220 were constructed by cloning the PSMEPb or RSV-controlled expression cassettes into ApaI/NotI sites in pOAdV600 or pOAdV200, respectively, that contain an infectious OAdV genome. 38, 39 Exact details of virus constructions are available on request. Viruses were rescued and propagated in CSL503 cells (sheep fetal lung cells), purified on CsCl density gradients, 40 desalted using NAP-25 columns (Amersham Pharmacia Biotech AB, Uppsala), and stored in TSP buffer containing 10 mM Tris HCl, pH 8, sucrose 8.5% (w/v) and 0.5% polyethylene glycol 400 (v/v). Buffer for formulated viruses also contained cationic lipid, 10mM CS087 (T-K3C7TL3), 41 and this was used as the vehicle control.
In vitro and in vivo transduction assay
Different cell lines were infected in triplicate with either OAdV623 or OAdV220 at an MOI of 10 2 -10 4 VP/cell and cell lysates were prepared at 1-4 days post infection. Aliquots of lysate (usually 5% of the total, except for highly infected HepG2 cells) were assayed for PNP activity as previously described. 4, 17 The PNP activity in lysates from OAdV623-infected cells was normalized with reference to PNP activity in equivalent amounts of lysate from OAdV220-infected cells. To assess PNP expression in vivo, mice were killed after intratumoral injection of 10 10 VP of OAdV623. Tumors were homogenized, and PNP activity was determined. 4, 17 
GDEPT in vivo
Human prostate cell lines were grown in adult male nude mice by subcutaneous (s.c.) injection of 2 Â 10 6 LN3 or 2.5 Â 10 6 PC3 cells in the rear flank. Once the tumors reached B5 Â 5 mm, mice were anesthetized with isoflurane (carried in 3% O 2 ; Abbott Australasia, Redwood City, CA, USA), and 20 ml of vector or formulation vehicle was injected into the tumors using 0.25 ml disposable syringes with a 29-gauge needle (Terumo, Elkton, MD, USA) that was moved to various sites in the tumor to maximize viral distribution. Next day, mice were given intraperitoneal (i.p.) prodrug, fludarabine phosphate (Schering, AG Germany), daily for 5 days at 75 mg/m 2 /day. Mice were grouped as: (1) 10 VP, for the PC3 study only). Mice were killed when the tumor was 15 Â 15 mm or if body weight loss exceeded 20%. At the time of killing, a portion of the tumor and several organs (draining lymph nodes, liver, spleen, kidney, lung, gut) from three mice/group were fixed for histology. In a separate experiment, PC3 tumors given GDEPT at 10 10 VP were harvested 3 and 7 days post virus injection for histology and immunohistochemistry.
Evaluation of tumor growth
Tumors were measured thrice weekly and tumor volumes (V) calculated as described. 42 Tumor growth
Prostate-targeted GDEPT for prostate cancer XY Wang et al was normalized for differing starting sizes by calculating relative tumor volume (RTV), the ratio of each tumor volume on each day relative to its volume on day (1). Tumor doubling time was the number of days for the median RTV of each group to reach 2. growth delay index, used to evaluate the change in tumor growth rate due to treatment, was calculated as treated tumor doubling time (days)/control tumor doubling time (days). The % optimum tumor growth inhibition, evaluated on selected measurement days before the first animal death due to tumor size in any group was calculated as 100 -(RTV treated/RTV vehicle control Â 100), based on the median RTV.
Tissue preparation/histology
Tissues were fixed in FAA buffer (50% ethanol, 3.2% formaldehyde, 4% glacial acetic acid) and paraffin embedded. Sections (5 mm) were stained with H&E. The extent of tumor necrosis or leukocyte infiltration into the tumor, the development of spontaneous metastases and toxic damage in various tissues were assessed.
Immunohistochemistry
Paraffin sections (5 mm) were stained for proliferating cells and apoptosis. Proliferating cells were detected by mouse anti-human Ki-67 19 (Dako, Carpinteria, CA, USA) using an Animal Research Kit (ARK, Dako). The Ki-67 primary antibody was biotinylated using Biotinylation Reagent, a modified biotinylated anti-mouse immunoglobulin (provided in ARK) before addition to tissue sections. A blocking reagent containing normal mouse serum was added to bind residual Biotinylation Reagent. Tissue sections were incubated with biotinylated Ki-67 Ab for 15 min, then with peroxidase-conjugated streptavidin for 15 min. Negative controls were incubated with subclass-matched, irrelevant mouse IgG1 kappa (Dako), instead of primary antibody. Apoptosis was detected using terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labelling (TUNEL) technique 18 with an in situ death detection kit, AP (Roche Diagnostics, Mannheim, Germany) as per the manufacturer's instructions. Stained sections were examined using a microscope (Leitz Laborlux S; Leica, Wetzlar, Germany) coupled to a video camera (Sony Hyper HAD, color CCD-IRIS/RGB, model DXC-151AP), connected to a computer equipped with an image analysis software program (Leica Qwin). From each section, 10 high-power microscopic fields (HPF) of highest positive areas were randomly selected, counted for positive cells within a fixed frame of 450 Â 450 pixels (0.1520 mm 2 ) , and averaged (number of positive cells/HPF).
Statistical analysis
Data were analyzed using GraphPad PRISM. To test for differences in tumor growth, RTV was compared between groups by one-way analysis of variance (ANOVA), and where significant, a Newman-Keuls post test was performed to find the groups that differed. Image analysis results were tested by the unpaired t-test. For mouse survival, treated and control groups were compared by a logrank test. A value of Po0.05 was considered significant.
